{"name":"REGENXBIO","slug":"regenxbio","ticker":"RGNX","exchange":"NASDAQ","domain":"regenxbio.com","description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States","hq":"Rockville, MD","founded":0,"employees":"371","ceo":"Curran Simpson","sector":"Gene Therapy / Rare Disease","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":6.42,"stockChange":-3.62,"stockChangePercent":-36.06,"marketCap":"$331M","metrics":{"revenue":170440992,"revenueGrowth":43,"grossMargin":-45.9,"rdSpend":228299000,"netIncome":-193878000,"cash":230070000,"dividendYield":0,"peRatio":-2.9,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"RGX-314 patent cliff ($1.4B at risk)","drug":"RGX-314","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"RGX-121 patent cliff ($200M at risk)","drug":"RGX-121","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"REGENXBIO reported its fourth quarter and full year 2023 financial results, with net loss of $83.6 million and $343.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"REGENXBIO Announces Collaboration with Sanofi to Develop Gene Therapies for Rare Diseases","summary":"REGENXBIO announced a collaboration with Sanofi to develop gene therapies for rare diseases, with an initial focus on AADC deficiency and Fabry disease.","drugName":"","sentiment":"positive"},{"date":"2023-08-07","type":"trial","headline":"REGENXBIO Announces Positive Interim Results from Phase 1/2 Clinical Trial of RGX-314 for Wet Age-Related Macular Degeneration","summary":"REGENXBIO announced positive interim results from a Phase 1/2 clinical trial of RGX-314 for wet age-related macular degeneration, with significant improvements in visual acuity and retinal thickness.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQUExUS005MENDWHRmeFY4Qk8yTXRIdkJSTzZDT1RRY0p6SWdRYndKRFRwN2hnZjBXa2RTTWxoY0tfSHc0eExYVmVXVTV1c2FFZnptOXZLcTZuQ1J3WUFLeVFVUXM1VTVWRjF6RjhnaDVFRUVBUHJSS3hacW9VY3VCQU5MTV9SR3BNOW12NnNLN19kMzBfSk9yN051STgwOG5hcmFkTlhSNzAwXzZuM3pZa1JUdnpqVGtpR1FoMkVYaFBtU3h0NjJjb1FWY0I4ZzFQeHVIM3RzWVYwMlRzQ09XVmExR3J1SVFHSzAwNjQ0OS1aVVk5SHQ5Mw?oc=5","date":"2026-03-13","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Neutral on These Healthcare Stocks: RegenXBio (RGNX), Roche Holding AG (RHHVF) - The Globe and Mail","headline":"Analysts Are Neutral on These Healthcare Stocks: RegenXBio (RGNX), Roche Holding AG (RHHVF)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQTVVZazFjTWNSR0txaDlmYWdOdFFrSW1FUHFfMXZKeEpPVmItTWw3VzF3X1FPbll2LVdpVWJSRjE5UGFzVmlUbURkMkdDdVplVE41R3EwNm5FbWVvSndRdWNza0Y0Rmc2ZjBlRkQ5VVhVSWJoSWpHZExGNk1LQUhzcWpuSHFSbTc0SnNRUVVGSGdWWFRwVmdaNnROQnNYR3dnZ21qZA?oc=5","date":"2026-03-13","type":"trial","source":"The Pharma Letter","summary":"Positive interim data for Regenxbio’s gene therapy in DMD - The Pharma Letter","headline":"Positive interim data for Regenxbio’s gene therapy in DMD","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOUndNcjIyVF9uc2pPNTlmSzN6Vy11aTJnQkxvWlN3b3JNSGtfRXgxOENGSC1fek1YaThRcG5XVXg3TUJTcEdkV1FSQmNFVnR3RUtKazZuR0dGMU83N0xjMndiQXRaMzF4cEJOVWJTWElZZ0E1aVE5T2pyaVJaYm9qdG8yNVNLZVVRNXRGLWVuTGRpVXZ2YnAxNzRGcVRvQ1pWamlQcGZsbUpndXIwcDB0NVRNWHV1di1fUUhaekE4aFUwelFUcU1HVnJkOFRiZFkwZmFrUVJ5Zw?oc=5","date":"2026-03-07","type":"deal","source":"The Globe and Mail","summary":"RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail","headline":"RBC Capital Reaffirms Their Buy Rating on RegenXBio (RGNX)","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNOVpfTENWWEoyOTlTSl9mTERpbEh5SlRDUTNZQ0pid2FCMDZBX3pnaENOV0liU294dEYyZm9WdnB2R1JoSW42elRjS095M3dXZ0JreExaWERMcWVaUnRUR1k0M0VsRGNYa0ZoaHpxMkZEb2JnT3FXYm9uYXhNSHNiTWVMcE91Tl9Ud3V2cFVwdHF3YXg2ckVPNVFlS2R6UlU?oc=5","date":"2026-02-10","type":"regulatory","source":"The Pharma Letter","summary":"US FDA rejection sends Regenxbio shares sharply lower - The Pharma Letter","headline":"US FDA rejection sends Regenxbio shares sharply lower","sentiment":"negative"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOERkNXNGX05jeWdQNWFrTFpCcW0yWDFKUlZLaFFRX2J0UHpxRTk4SVdaOUdlOS11WUF3Q2xHOEloU2JvUUFvUGhJb283TmV2Tm9SRkdpRTNNSzRpdVNZU3E4MG5IdDl5Zk9USTR3X1JFZTlXTFlBR2NKZVBvM28yVjcwOVZZdjBtTDhZMENkUmVldm9vclAxNFg4UmQ0WWdTWnFLR3NzVGRuZlRVTmNYVjlkdW1LcHg3MF94V0kzdWpXQQ?oc=5","date":"2026-02-09","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Regenxbio's gene therapy for rare disease - Reuters","headline":"US FDA declines to approve Regenxbio's gene therapy for rare disease","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"pipeline","source":"simplywall.st","summary":"REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - simplywall.st","headline":"REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOSkgxbnV2N2t4aVJDTFNmTFAtcTRhbU1FMHB4V2pYV1dqQm5KWEVZdEtObjJTWXVTc1E1TXJMaUI5V3JmMVQ4bk5KR3ZQeFQtLVp5YUpqUTRsV0ZtcW5OTThhLTFCckNDcmdwMF9HbGV5aGlMdFN2ZjBfQS1YeXFQY2RnSHRQT3d0MG9oUUhDQ0twVGtSYkpDRWZrOExXcTN6bUhTMTd0akRTLU51UDZ4OVdYZ3pXQTFDTGZ5WQ?oc=5","date":"2026-02-01","type":"regulatory","source":"MedCity News","summary":"Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease - MedCity News","headline":"Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-01-29","type":"pipeline","source":"simplywall.st","summary":"Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load? - simplywall.st","headline":"Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNeWJXdjk2dDdUaFVid0NrMmdrTUo4QkpMeTlwOVI5NVl4LXY5ZnpYSnhFX1hFTTRIUngxNUFxNFJZUjUzeUdITm51M2Z1TmdjdHB0ZGJyZExqSVltZHFKZHhHSVVHcVcyT3VXNDBiUE4tOHZQMTlMOEZNdlJPSVEyenBILTJpM0M2a0Vsb0pkRkpzdWE2OGozR1l2ZmQ3ZWFqcEx3T0M4ZjlxZFZleG1ZRU55UUVrVGRFMXhxQmkyeGJ2TnFmTUN0aTRn?oc=5","date":"2026-01-28","type":"regulatory","source":"Reuters","summary":"US FDA places clinical hold on Regenxbio's rare disease program - Reuters","headline":"US FDA places clinical hold on Regenxbio's rare disease program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOUFEyemlkaGF3elVvdWxnTEppbW1iN211SGRfNFFmeU1mN0NzakY2ZUpPM3BPbExJeU9zcUdNTWN0SnlzT0cxdmlxa2VaMS16Q0c3QzRNRVd0dkRmNm5DWmFYamgyX3oteUtkOFdXOWNKZEVwSnJYRDhhWk9La21ObmZEN2NzX2cyNGNWX1JnZG5NNFNM?oc=5","date":"2026-01-28","type":"regulatory","source":"PharmaLive","summary":"US FDA places clinical hold on Regenxbio’s rare disease program - PharmaLive","headline":"US FDA places clinical hold on Regenxbio’s rare disease program","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"RGX-314","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"RGX-121","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Spark Therapeutics","Editas Medicine","Crucell"],"therapeuticFocus":["Gene Therapy","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":10393000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":10393000,"period":"2017-12-31"},{"value":2040000,"period":"2017-12-31"},{"value":1336000,"period":"2017-09-30"},{"value":6562000,"period":"2017-06-30"},{"value":455000,"period":"2017-03-31"}],"grossProfit":150143000,"grossProfitHistory":[{"period":"2025-12-31","value":150143000},{"period":"2024-12-31","value":49761000},{"period":"2023-12-31","value":53029000},{"period":"2022-12-31","value":58179000}],"rdSpend":228299000,"rdSpendHistory":[{"period":"2025-12-31","value":228299000},{"period":"2024-12-31","value":208522000},{"period":"2023-12-31","value":232266000},{"period":"2022-12-31","value":242453000}],"sgaSpend":82863000,"operatingIncome":-161198000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-161198000},{"period":"2024-12-31","value":-231245000},{"period":"2023-12-31","value":-268128000},{"period":"2022-12-31","value":-262876000}],"netIncome":-193878000,"netIncomeHistory":[{"period":"2025-12-31","value":-193878000},{"period":"2024-12-31","value":-227102000},{"period":"2023-12-31","value":-263494000},{"period":"2022-12-31","value":-280321000}],"eps":-4.59,"epsHistory":[{"period":"2024-12-31","value":-4.59},{"period":"2023-12-31","value":-6.02},{"period":"2022-12-31","value":-6.5},{"period":"2021-12-31","value":2.91}],"cash":34466000,"cashHistory":[{"period":"2025-12-31","value":34466000},{"period":"2024-12-31","value":57526000},{"period":"2023-12-31","value":34522000},{"period":"2022-12-31","value":96952000}],"totalAssets":453032000,"totalLiabilities":350299000,"totalDebt":73501000,"equity":102733000,"operatingCashflow":-123963000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-123963000},{"period":"2024-12-31","value":-173125000},{"period":"2023-12-31","value":-218407000},{"period":"2022-12-31","value":-207488000}],"capex":-2414000,"capexHistory":[{"period":"2025-12-31","value":-2414000},{"period":"2024-12-31","value":-2436000},{"period":"2023-12-31","value":-9960000},{"period":"2022-12-31","value":-30724000}],"freeCashflow":-126377000,"dividendsPaid":null,"buybacks":null,"employees":371,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22380000,"ebit":-54873000,"ebitda":-51004000,"period":"2025-12-31","revenue":30337000,"epsBasic":-1.3,"netIncome":-67149000,"rdExpense":59611000,"epsDiluted":-1.3,"grossProfit":24409000,"operatingIncome":-57636000},{"sga":20253000,"ebit":-48772000,"ebitda":-44886000,"period":"2025-09-30","revenue":29733000,"epsBasic":-1.2,"netIncome":-61941000,"rdExpense":56101000,"epsDiluted":-1.2,"grossProfit":24008000,"operatingIncome":-52411000},{"sga":19883000,"ebit":-59878000,"ebitda":-55973000,"period":"2025-06-30","revenue":21359000,"epsBasic":-1.38,"netIncome":-70871000,"rdExpense":59500000,"epsDiluted":-1.38,"grossProfit":16150000,"operatingIncome":-63278000},{"sga":20347000,"ebit":14653000,"ebitda":18608000,"period":"2025-03-31","revenue":89012000,"epsBasic":0.12,"netIncome":6083000,"rdExpense":53087000,"epsDiluted":0.12,"grossProfit":85576000,"operatingIncome":12127000},{"sga":20051000,"ebit":-41769000,"ebitda":-37746000,"period":"2024-12-31","revenue":21214000,"epsBasic":-1.01,"netIncome":-51186000,"rdExpense":50380000,"epsDiluted":-1.01,"grossProfit":14896000,"operatingIncome":-51368000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.42,"previousClose":10.04,"fiftyTwoWeekHigh":16.19,"fiftyTwoWeekLow":6.01,"fiftyTwoWeekRange":"6.015 - 16.19","fiftyDayAverage":9,"twoHundredDayAverage":10.58,"beta":1.12,"enterpriseValue":548642368,"forwardPE":-2.9,"priceToBook":3.18,"priceToSales":1.94,"enterpriseToRevenue":3.22,"enterpriseToEbitda":-3.77,"pegRatio":0,"ebitda":-145583008,"ebitdaMargin":-85.4,"freeCashflow":-79794752,"operatingCashflow":-123963000,"totalDebt":260518000,"debtToEquity":253.6,"currentRatio":2.38,"returnOnAssets":-21.9,"returnOnEquity":-107,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":27.82,"targetHighPrice":50,"targetLowPrice":12,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.8,"institutionHeldPercent":82.3,"sharesOutstanding":51617233,"floatShares":42998261,"sharesShort":6692556,"shortRatio":11.92,"shortPercentOfFloat":13,"epsTrailing":-3.76,"epsForward":-2.2,"revenuePerShare":3.31,"bookValue":2.02,"officers":[{"age":63,"name":"Mr. Curran M. Simpson M.S.","title":"President, CEO & Director"},{"age":54,"name":"Mr. Patrick J. Christmas II, J.D.","title":"Executive VP & Chief Strategy and Legal Officer"},{"age":56,"name":"Dr. Stephen  Pakola M.D.","title":"Executive VP & Chief Medical Officer"},{"age":44,"name":"Mr. Mitchell  Chan M.B.A.","title":"Executive VP & CFO"},{"age":52,"name":"Mr. Craig  Malzahn","title":"Executive VP of Product Development & CTO"},{"age":67,"name":"Dr. Olivier  Danos Ph.D.","title":"Executive VP & Chief Scientific Officer"},{"age":null,"name":"Ms. Shiva G. Fritsch","title":"Chief Communications & People Officer"},{"age":49,"name":"Dr. Ram  Palanki Pharm.D.","title":"Executive VP & Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.regenxbio.com","phone":"240 552 8181"}}